Victoza (liraglutide) is a GLP-1 (glucagon-like peptide) analogue, approved as add-on therapy to metformin or sulfonylurea (SU), and as add-on to combination therapy with metformin and SU/glitazone for the treatment of type 2-diabetes.
The long term effect and long term side effects are not known yet.
Liraglutide 1,2 and 1,8 mg is not significantly worse than glimepiride and is in the highest dose (1,8 mg) significantly better than exenatide and insulin glargine in reducing HbA1c after 26 weeks of add-on to metformin and/or glimepiride.
Treatment with liraglutide induces a placebo corrected weight loss at around 1 kg. Compared to exenatide the weight loss is similar.
Nausea is the most frequent side effect. The incidence, however, declines over time.
Liraglutide causes fewer mild hypoglycaemic incidences than glimepiride and exenatide.
Liraglutide 1,2 and 1,8 mg costs 32 and 48 Dkr. per dose and is consequently more expensive than comparable doses of glimepiride, exenatide and insulin glargine.
IRF states that Victoza can be considered in obese patients with type 2-diabetes, where blood sugar levels cannot be controlled on a combination of healthy lifestyle, metformin and SU.
Victoza was marketed the 27th of July 2009. Victoza is under the rules of general reimbursement.